Cancer Stem Cells and New Therapeutic Approaches

Cancer Stem Cells: Identification and Targets

Volumn , Issue , 2008, Pages 217-232

  Dean, Michael ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer stem cells and new therapeutic approaches; Chemotherapeutic drug transporter targets; Tumor types and stem cell activation

Indexed keywords

EID: 77955662090     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470391594.ch11     Document Type: Chapter

References (66)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100:3983-3988.
2. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003; 100:15178-15183.
3. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004; 101:14228-14233.
4. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stemlike cells in the C6 glioma cell line. Proc Natl Acad Sci U S A. 2004; 101:781-786.
5. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955; 9:539-549.
6. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001; 7:1028-1034.
7. Kim M, Turnquist H, Jackson J, et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res. 2002; 8:22-28.
8. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002; 99:507-512.
9. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004; 432:324-331.
10. Tennant R. What is a tumor promoter? Environ Health Perspect. 1999; 107:A390-A391.
11. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci U S A. 1993; 90:10914-10921.
12. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68:820-823.
13. Hahn H, Christiansen J,Wicking C, et al. A mammalian patched homolog is expressed in target tissues of Sonic Hedgehog and maps to a region associated with developmental anomalies. J Biol Chem. 1996; 271:12125-12128.
14. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996; 85:841-851.
15. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996; 272:1668-1671.
16. Dean M. Towards a unified model of tumor suppression: lessons learned from the human patched gene. Biochim Biophys Acta. 1997; 1332:M43-M52.
17. Trichopoulos D, Lagiou P, Adami HO. Towards an integrated model for breast cancer etiology: the crucial role of the number of mammary tissue-specific stem cells. Breast Cancer Res. 2005; 7:13-17.
18. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81:1879-1886.
19. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346:1609-1615.
20. Eaden J. Colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther. 2004; 20:24-30.
21. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991; 66:589-600.
22. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 1991; 253:665-669.
23. Gardner EJ. Follow-up study of a family group exhibiting dominant inheritance for a syndrome including intestinal polyps, osteomas, fibromas and epidermal cysts. Am J Hum Genet. 1962; 14:376-390.
24. Deschner EE, Lipkin M. Proliferative patterns in colonic mucosa in familial polyposis. Cancer 1975; 35(2): 413-418
25. Moser AR, Dove WF, Roth KA, Gordon JI. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol. 1992; 116:1517-1526.
26. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 1992; 256:668-670.
27. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996; 87:159-170.
28. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74-108.
29. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 1981; 2:1129-1133.
30. Yu MC, Tong MJ, Coursaget P, Ross RK, Govindarajan S, Henderson BE. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst. 1990; 82:1038-1041.
31. Millward MJ, Cantwell BM, Munro NC, Robinson A, Corris PA, Harris AL. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer. 1993; 67:1031-1035.
32. West KA, Brognard J, Clark AS, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest. 2003; 111:81-90.
33. Hughes J, Weil H. Lung biology in health and disease. In Samet J, ed. Epidemiology of Lung Cancer. New York: Marcel Dekker; 1994; 74:185-205.
34. Knudson A. Asbestos and mesothelioma: genetic lessons from a tragedy. Proc Natl Acad Sci U S A. 1995; 92:10819-10820.
35. Wu-Williams AH, Yu MC, Mack TM. Life-style, workplace, and stomach cancer by subsite in young men of Los Angeles County. Cancer Res. 1990; 50:2569-2576.
36. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345:784-789.
37. Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control. 2000; 11:915-923.
38. Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res. 1988; 48:6912-6917.
39. Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir. 2004; 59:99-111.
40. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996; 56:5360-5364.
41. Zur Hausen H, Meinhof W, Scheiber W, Bornkamm GW. Attempts to detect virus-specific DNA in human tumors: I. Nucleic acid hybridizations with complementary RNA of human wart virus. Int J Cancer. 1974; 13:650-656.
42. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990; 248:76-79.
43. Tommasino M, Crawford L. Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Bioessays. 1995; 17:509-518.
44. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002; 2:59-65.
45. Sasadeusz J, Kelly H, Szer J, Schwarer AP, Mitchell H, Grigg A. Abnormal cervical cytology in bone marrow transplant recipients. Bone Marrow Transplant. 2001; 28:393-397.
46. Nakachi K, Hayashi T, Imai K, Kusunoki Y. Perspectives on cancer immunoepidemiology. Cancer Sci. 2004; 95:921-929.
47. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002; 29:15-18.
48. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2:48-58.
49. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996; 183:1797-1806.
50. Dean M, Fojo T, Bates S. Tumor stem cells and drug resistance. Nat Rev Cancer. 2005; 5:275-284.
51. Henrich CJ, Bokesch HR, Dean M, et al. A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen. 2006; 11:176-183.
52. Nusslein-Volhard C,Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980; 287:795-801.
53. Chidambaram A, Goldstein AM, Gailani MR, et al. Mutations in the human homolog of the Drosophila patched gene in Caucasian and African American nevoid basal cell carcinoma syndrome patients. Cancer Res. 1996; 56:4599-4601.
54. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996; 14:78-81.
55. Bale AE, Yu KP. The Hedgehog pathway and basal cell carcinomas. Hum Mol Genet. 2001; 10:757-762.
56. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumors. Nature. 2003; 425:846-851.
57. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003; 425:851-856.
58. Watkins DN, Berman DM, Burkholder SG,Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature. 2003; 422:313-317.
59. Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004; 431:707-712.
60. James LF, Panter KE, Gaffield W, Molyneux RJ. Biomedical applications of poisonous plant research. J Agric Food Chem. 2004; 52:3211-3230.
61. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev. 2002; 16:2743-2748.
62. Athar M, Li C, Tang X, et al. Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res. 2004; 64:7545-7552.
63. Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP. Repression of smoothened by patched -dependent (pro-)vitamin D3 secretion. PLoS Biol. 2006; 4.
64. Fan X, MatsuiW, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006; 66:7445-7452.
65. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988; 48:589-601.
66. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977; 197:461-463.